Robert J. Fram
Plus aucun poste en cours
Profil
Robert J.
Fram is Chief Medical Officer of Mersana Therapeutics, Inc. Most recently, Dr. Fram was Vice President of Clinical Development for ImmunoGen.
Prior to ImmunoGen, he worked with Vertex Pharmaceuticals, Ilex Oncology, and Knoll Pharmaceuticals.
Dr. Fram was a Principal at Dana Farber Cancer Institute and Harvard Medical School and as an Associate Professor of Medicine at the University of Massachusetts Medical School and at the University of Maryland Cancer Center.
He was a Clinical Associate Professor of Medicine at the Brown University Medical School.
Dr. Fram has 28 years of experience in medical oncology.
He received an AB degree from Harvard College in 1971 and an MD from Harvard Medical School in 1976.
Dr. Fram completed his Post-Doctoral Training in Internal Medicine at Columbia Presbyterian Medical Center and in Hematology and Oncology at Dana Farber Cancer Institute and Brigham and Women's Hospital in Boston.
Anciens postes connus de Robert J. Fram
| Sociétés | Poste | Fin |
|---|---|---|
| University of Maryland | Corporate Officer/Principal | - |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
| University of Massachusetts | Corporate Officer/Principal | - |
| ABBOTT INDIA LIMITED | Corporate Officer/Principal | - |
ILEX Oncology, Inc.
 ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Corporate Officer/Principal | - |
Formation de Robert J. Fram
| Harvard University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| IMMUNOGEN, INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| ABBOTT INDIA LIMITED | Health Technology |
| Entreprise privées | 2 |
|---|---|
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
